Aspira Pathlab & Diagnostics Ltd (BSE: 540788) is a Mumbai, Maharashtra-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹127 Cr, it ranks #3,045 by market cap among the 6,197 Indian listed companies on FinBizNet, and #9 of 18 in Medical Diagnostic Centres. At ₹129.15 (as of 16 Nov 2026), the share price is 13.9% below its 52-week high of ₹149.99 and 139.2% above its 52-week low of ₹54.00. The share price is up 115.2% over one year and up 27.2% over three months.
| Current Price | ₹129.15 |
|---|---|
| Market Cap | ₹127 Cr |
| BSE Code | 540788 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Services > Medical Diagnostic Centres |
| P/E Ratio | 2,360 |
| Return on Assets | -0.26% |
| 52-Week Range | ₹54.00 – ₹149.99 |
| 1-Year Price Change | +115.2% |
| 3-Month Price Change | +27.2% |
| Beta (1Y) | -0.32 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.aspiradiagnostics.com |
Delivery averaged 82.1% of traded volume across 6 BSE sessions (3 Nov 2026 – 13 Nov 2026).
Aspira Pathlab & Diagnostics Limited owns, manages, runs, and administers various diagnostics centers primarily in India. The company offers biochemistry, hematology, histopathology, microbiology, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigation services. It also provides sonography, x-ray, and radiology tests. The company was formerly known as Utkal Soap Products Limited and changed its name to Aspira Pathlab & Diagnostics Limited in November 2016. Aspira Pathlab & Diagnostics Limited was incorporated in 1973 and is based in Mumbai, India.
1. Pathology and Diagnostics-This segment operates diagnostic centers.
1. Pathology and Diagnostics-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Dr. Lal Pathlabs Ltd | ₹33,934 Cr | 66.4 | 21.48% | ₹874 Cr | +28.7% |
| Vijaya Diagnostic Centre Limited | ₹14,665 Cr | 84.3 | 19.70% | ₹255 Cr | +38.5% |
| Metropolis Healthcare Limited | ₹11,952 Cr | 61.5 | 13.37% | ₹497 Cr | +14.9% |
| Throcare Technologies Ltd | ₹7,764 Cr | 47.6 | 28.74% | ₹271 Cr | +7.5% |
| SURAKSHA DIAGNOSTIC LIMITED | ₹1,856 Cr | 55.4 | 13.84% | ₹99 Cr | +6.9% |
| Krsnaa Diagnostics Ltd | ₹1,625 Cr | 16.8 | 10.89% | ₹271 Cr | -27.0% |
| Gaudium IVF and Women Health Limited | ₹803 Cr | 27.4 | 16.08% | ₹37 Cr | — |
| Chandan Healthcare Limited | ₹582 Cr | 21.9 | 18.43% | ₹81 Cr | — |
| Aspira Pathlab & Diagnostics Ltd | ₹127 Cr | 2,360 | — | — | +115.2% |
Listed by market capitalisation. Ratios are shown for context only.
Aspira Pathlab & Diagnostics Ltd is trading at ₹129.15, with a market capitalisation of ₹127 Cr.
Aspira Pathlab & Diagnostics Ltd operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).
Aspira Pathlab & Diagnostics Ltd has a P/E of 2,360.
Aspira Pathlab & Diagnostics Ltd is listed on the BSE under the scrip code 540788.
Aspira Pathlab & Diagnostics Ltd's share price is up 115.2% over one year and up 27.2% over three months. Its 52-week range is ₹54.00 to ₹149.99.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.